Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry

SIMPLE SUMMARY: The use of azacitidine (AZA) and decitabine (DEC) have allowed more elderly acute myeloid leukemia (AML) patients to be treated. However, scarcely any direct comparative data exist between both drugs. This study shows no significant differences in response rates or overall survival (...

Descripción completa

Detalles Bibliográficos
Autores principales: Labrador, Jorge, Martínez-Cuadrón, David, de la Fuente, Adolfo, Rodríguez-Veiga, Rebeca, Serrano, Josefina, Tormo, Mar, Rodriguez-Arboli, Eduardo, Ramos, Fernando, Bernal, Teresa, López-Pavía, María, Trigo, Fernanda, Martínez-Sánchez, María Pilar, Rodríguez-Gutiérrez, Juan-Ignacio, Rodríguez-Medina, Carlos, Gil, Cristina, Belmonte, Daniel García, Vives, Susana, Foncillas, María-Ángeles, Pérez-Encinas, Manuel, Novo, Andrés, Recio, Isabel, Rodríguez-Macías, Gabriela, Bergua, Juan Miguel, Noriega, Víctor, Lavilla, Esperanza, Roldán-Pérez, Alicia, Sanz, Miguel A., Montesinos, Pau
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9105404/
https://www.ncbi.nlm.nih.gov/pubmed/35565471
http://dx.doi.org/10.3390/cancers14092342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9105404/
https://www.ncbi.nlm.nih.gov/pubmed/35565471
http://dx.doi.org/10.3390/cancers14092342

Ejemplares similares